Wells Fargo & Company Amicus Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 414,589 shares of FOLD stock, worth $3.95 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
414,589
Previous 610,786
32.12%
Holding current value
$3.95 Million
Previous $6.06 Million
26.92%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding FOLD
# of Institutions
312Shares Held
314MCall Options Held
516KPut Options Held
833K-
Vanguard Group Inc Valley Forge, PA28.8MShares$274 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY28.1MShares$267 Million7.83% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$232 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA24MShares$228 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY23.2MShares$221 Million3.72% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.67B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...